Human leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma

Genes Chromosomes and Cancer

Volumn 54, Issue 3, 2015, Pages 185-193

  Bielska, Marta ^a   Bojo, Marcin ^b   Klimkiewicz Wojciechowska, Gabriela ^a   Jesionek Kupnicka, Dorota ^a   Borowiec, Maciej ^a   Kalinka Warzocha, Ewa ^b   Prochorec Sobieszek, Monika ^c   Robak, Tadeusz ^a   Warzocha, Krzysztof ^c   Młynarski, Wojciech ^a   Lech Maranda, Ewa ^c,d  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b M Kopernik Hospital   (Poland)

^c INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^d MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

HLA G ANTIGEN;

ARTICLE; CANCER MORTALITY; DISEASE COURSE; GENE DELETION; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; ADULT; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MORTALITY;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HLA-G ANTIGENS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; POLYMORPHISM, GENETIC;

EID: 84921505548     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22235     Document Type: Article

References (30)

1. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. 2008. HLA-G: From biology to clinical benefits. Trends Immunol 29:125-132.
2. Catamo E, Addobbati C, Segat L, Sotero Fragoso T, Domingues Barbosa A, Tavares Dantas A, de Ataíde Mariz H, da Rocha LF, Jr, Branco Pinto Duarte AL, Monasta L, Sandrin-Garcia P, Crovella S. 2014. HLA-G gene polymorphisms associated with susceptibility to rheumatoid arthritis disease and its severity in Brazilian patients. Tissue Antigens 83:308-315.
3. Chen XY, Yan WH, Lin A, Xu HH, Zhang JG, Wang XX. 2008. The 14 bp deletion polymorphisms in HLA-G gene play an important role in the expression of soluble HLA-G in plasma. Tissue Antigens 72:335-341.
4. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. 1999. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244.
5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242.
6. Ding K, Zhou K, He F, Shen Y. 2003. LDA-A java-based linkage disequilibrium analyzer. Bioinformatics 19:2147-2148.
7. Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M, Rey D, Moreau P. 2011. Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association. Cell Mol Life Sci 68:369-395.
8. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. 2005. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126.
9. Ge YZ, Ge Q, Li MH, Shi GM, Xu X, Xu LW, Xu Z, Lu TZ, Wu R, Zhou LH, Wu JP, Liang K, Dou QL, Zhu JG, Li WC, Jia RP. 2014. Association between human leukocyte antigen-G 14-bp insertion/deletion polymorphism and cancer risk: A meta-analysis and systematic review. Hum Immunol 75:827-832.
10. Giannopoulos K, Schmitt M, Kowal M, Własiuk P, Bojarska-Junak A, Roliński J, Dmoszyńska A. 2008. The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL). Leuk Res 32:1815-1819.
11. Hviid TV, Hylenius S, Rørbye C, Nielsen LG. 2003. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 55:63-79.
12. Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR. 2004. HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics 56:135-141.
13. Jassem RM, Shani WS, Loisel DA, Sharief M, Billstrand C, Ober C. 2012. HLA-G polymorphisms and soluble HLA-G protein levels in women with recurrent pregnancy loss from Basrah province in Iraq. Hum Immunol 73:811-817.
14. Juszczynski P, Kalinka E, Bienvenu J, Woszczek G, Borowiec M, Robak T, Kowalski M, Lech-Maranda E, Baseggio L, Coiffier B, Salles G, Warzocha K. 2002. Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood 100:3037-340.
15. Larsen MH, Hviid TV. 2009. Human leukocyte antigen-G polymorphism in relation to expression, function, and disease. Hum Immunol 70:1026-1034.
16. Lefebvre S, Moreau P, Guiard V, Ibrahim EC, Adrian-Cabestre F, Menier C, Dausset J, Carosella ED, Paul P. 1999. Molecular mechanisms controlling constitutive and IFN-gamma-inducible HLA-G expression in various cell types. J Reprod Immunol 43:213-224.
17. LeMaoult J, Le Discorde M, Rouas-Freiss N, Moreau P, Menier C, McCluskey J, Carosella ED. 2003. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 62:273-284.
18. Loustau M, Wiendl H, Ferrone S, Carosella ED. 2013. HLA-G 2012 conference: The 15-year milestone update. Tissue Antigens 81:127-136.
19. Lu Y, Abdou AM, Cerhan JR, Morton LM, Severson RK, Davis S, Cozen W, Rothman N, Bernstein L, Chanock S, Hartge P, Wang SS. 2011. Human leukocyte antigen class I and II alleles and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Sci World J 11:2062-2070.
20. Michallet AS, Coiffier B. 2009. Treatment of patients with diffuse large B-cell lymphoma. Haematologica 1:29-40.
21. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. 2005. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 105:1694-1698.
22. Ober C, Aldrich CL, Chervoneva I, Billstrand C, Rahimov F, Gray HL, Hyslop T. 2003. Variation in the HLA-G Promoter Region Influences Miscarriage Rates. Am J Hum Genet 72:1425-1435.
23. Ober C, Billstrand C, Kuldanek S, Tan Z. 2006. The miscarriage-associated HLA-G -725G allele influences transcription rates in JEG-3 cells. Hum Reprod 21:1743-1748.
24. Rebmann V, Nuckel H, Duhrsen U, Hans Grosse-Wilde H. 2007. HLA-G in B-chronic lymphocytic leukaemia: Clinical relevance and functional implications. Semin Cancer Biol 17:430-435.
25. Rizzo R, Audrito V, Vacca P, Rossi D, Brusa D, Stignani M, Bortolotti D, D'Arena G, Coscia M, Laurenti L, Forconi F, Gaidano G, Mingari MC, Moretta L, Malavasi F, Deaglio S. 2014. HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: Impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica 99:888-896.
26. Rousseau P, Le Discorde M, Mouillot G, Marcou C, Carosella ED, Moreau P. 2003. The 14 bp deletion-insertion polymorphism in the 3′ UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol 64:1005-1110.
27. Sebti Y, Le Maux A, Gros F, de Guibert S, Pangault C, Rouas-Freiss N, Bernard M, Amiot L. 2007. Expression of functional soluble human leucocyte antigen-G molecules in lymphoproliferative disorders. Br J Haematol 138:202-212.
28. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, MacPherson N, O'Reilly S, Spinelli JJ, Sutherland J, Wilson KS, Gascoyne RD, Connors JM. 2005. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23:5027-5533.
29. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. 2008. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press.
30. Wang SS, Abdou AM, Morton LM, Thomas R, Cerhan JR, Gao X, Cozen W, Rothman N, Davis S, Severson RK, Bernstein L, Hartge P, Carrington M. 2010. Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood 115:4820-4823.